Article: Kibow Biotech Enters US Consumer Dietary Supplement Market with Kibow Flora(TM) and Three Related Products Targeting the Risk Factors of Metabolic Syndrome.

PHILADELPHIA, Nov. 14 /PRNewswire/ -- Kibow Biotech, Inc. marked its first decade of activity by announcing today the launch of Kibow Flora(TM), the first probiotic and prebiotic combination specifically developed for Metabolic Syndrome. Metabolic Syndrome (also referred to as Syndrome-X), is a disorder affecting an estimated 22% of US adults and 4.2% of US adolescents.

In addition to Kibow Flora(TM), the Company's new Metabolic Syndrome range includes three related products -- Kibow C-12 peptide, Kibow Acetyl-L- Carnitine and Kibow L-Theanine. According to the indication, each product may be taken separately or together with Kibow Flora. All ingredients in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!